Effect of the Interaction Between Atorvastatin and Selective Serotonin Reuptake Inhibitors on the Blood Redox Equilibrium

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2016 Nov 25

PMID 27882176

Citations 4

Authors

Mariola Herbet

Monika Gawronska-Grzywacz

Magdalena Izdebska

Iwona Piatkowska-Chmiel

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease and depression often occur simultaneously in the same patient. Long-term polypharmacotherapy can lead to drug-induced oxidative stress. Data concerning the effects of concomitant treatment with atorvastatin and selective serotonin reuptake inhibitors (SSRIs) are lacking. The aim of the present study was to examine oxidative stress parameters in the blood of rats after 28 days treatment with atorvastatin combined with fluoxetine or paroxetine. The study was carried out on male Wistar rats weighing 200-250 g. Aqueous solutions of atorvastatin (10 mg/kg), fluoxetine (10 mg/kg) and paroxetine (10 mg/kg) were injected once a day for 28 days, separately or concomitantly. The activity of glutathione peroxidase (GPX) was determined in the whole blood, whereas the activity of glutathione reductase (GR) and the total antioxidant status (TAS) were determined in the serum. The results demonstrated that concomitant administration of atorvastatin with fluoxetine caused an increase in the GPX activity and the TAS. Atorvastatin administered to rats with paroxetine increased the activities of GPX and GR. In the groups of rats receiving atorvastatin or SSRIs separately, no statistically significant changes in the investigated parameters were observed. The changes that were detected may indicate an increase in endogenous antioxidant levels during the concomitant application of atorvastatin with SSRIs and thus a drug-drug interaction having an effect on the blood redox equilibrium.

Citing Articles

The Novel Imipramine-Magnesium Complex Exerts Antidepressant-like Activity in Mice Subjected to the Forced Swim Test and the Tail Suspension Test.

Serefko A, Lachowicz-Radulska J, Szopa A, Herbet M, Czylkowska A, Ignatiuk K Molecules. 2025; 30(3).

PMID: 39942624 PMC: 11820773. DOI: 10.3390/molecules30030519.

The Influence of Atorvastatin Treatment on Homocysteine Metabolism and Oxidative Stress in an Experimental Model of Diabetic Rats.

Clim A, Maranduca M, Filip N, Tanase D, Floria M, Pinzariu A Life (Basel). 2024; 14(11).

PMID: 39598213 PMC: 11595749. DOI: 10.3390/life14111414.

Syrosingopine and UK5099 synergistically suppress non-small cell lung cancer by activating the integrated stress response.

Li Y, Song Y, Shi Z, Hou H, Yu Y, Pan F Cell Death Dis. 2024; 15(6):431.

PMID: 38898028 PMC: 11187063. DOI: 10.1038/s41419-024-06821-4.

Fluoxetine scaffold to design tandem molecular antioxidants and green catalysts.

Ribaudo G, Bortoli M, Ongaro A, Oselladore E, Gianoncelli A, Zagotto G RSC Adv. 2022; 10(32):18583-18593.

PMID: 35518299 PMC: 9053872. DOI: 10.1039/d0ra03509b.

Radical Scavenging Potential of the Phenothiazine Scaffold: A Computational Analysis.

Dalla Tiezza M, Hamlin T, Bickelhaupt F, Orian L ChemMedChem. 2021; 16(24):3763-3771.

PMID: 34536069 PMC: 9292796. DOI: 10.1002/cmdc.202100546.

References

Nelson J, Kennedy J, Pollock B, Narayan M, Nobler M, Robin D . Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Psychiatry. 1999; 156(7):1024-8. DOI: 10.1176/ajp.156.7.1024. View

Kobayashi J, Maruyama T, Masuda M, Shinomiya M . Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin Chim Acta. 2001; 314(1-2):261-4. DOI: 10.1016/s0009-8981(01)00701-x. View

Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R . Safety considerations for statins. Curr Opin Lipidol. 2002; 13(6):637-44. DOI: 10.1097/00041433-200212000-00007. View

Vaswani M, Linda F, Ramesh S . Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(1):85-102. DOI: 10.1016/s0278-5846(02)00338-x. View

Lins R, Matthys K, Verpooten G, Peeters P, Dratwa M, Stolear J . Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant. 2003; 18(5):967-76. DOI: 10.1093/ndt/gfg048. View

Roose S . Treatment of depression in patients with heart disease. Biol Psychiatry. 2003; 54(3):262-8. DOI: 10.1016/s0006-3223(03)00320-2. View

Roose S, Miyazaki M . Pharmacologic treatment of depression in patients with heart disease. Psychosom Med. 2005; 67 Suppl 1:S54-7. DOI: 10.1097/01.psy.0000163455.43226.bf. View

Sirtori C, Fumagalli R . LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention. A lesson from cholesterol turnover studies and others. Atherosclerosis. 2005; 186(1):1-11. DOI: 10.1016/j.atherosclerosis.2005.10.024. View

Thombs B, Bass E, Ford D, Stewart K, Tsilidis K, Patel U . Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med. 2006; 21(1):30-8. PMC: 1484630. DOI: 10.1111/j.1525-1497.2005.00269.x. View

10.

Guengerich F . Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006; 8(1):E101-11. PMC: 2751428. DOI: 10.1208/aapsj080112. View

11.

Zafir A, Banu N . Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol. 2007; 572(1):23-31. DOI: 10.1016/j.ejphar.2007.05.062. View

12.

Cangemi R, Loffredo L, Carnevale R, Perri L, Patrizi M, Sanguigni V . Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E. Eur Heart J. 2007; 29(1):54-62. DOI: 10.1093/eurheartj/ehm565. View

13.

Frasure-Smith N, Lesperance F, Irwin M, Talajic M, Pollock B . The relationships among heart rate variability, inflammatory markers and depression in coronary heart disease patients. Brain Behav Immun. 2009; 23(8):1140-7. DOI: 10.1016/j.bbi.2009.07.005. View

14.

Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S . Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep. 2009; 61(5):892-8. DOI: 10.1016/s1734-1140(09)70146-x. View

15.

Jornil J, Jensen K, Larsen F, Linnet K . Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2009; 38(3):376-85. DOI: 10.1124/dmd.109.030551. View

16.

Bloom H, Shukrullah I, Veledar E, Gutmann R, London B, Dudley S . Statins Decrease Oxidative Stress and ICD Therapies. Cardiol Res Pract. 2010; 2010:253803. PMC: 2847377. DOI: 10.4061/2010/253803. View

17.

Park B, Laverty H, Srivastava A, Antoine D, Naisbitt D, Williams D . Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chem Biol Interact. 2010; 192(1-2):30-6. DOI: 10.1016/j.cbi.2010.09.011. View

18.

Koksal M, Eren M, Turan M, Sabuncu T . The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients. Eur J Intern Med. 2011; 22(3):249-53. DOI: 10.1016/j.ejim.2010.12.003. View

19.

Novio S, Nunez M, Amigo G, Freire-Garabal M . Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice. Basic Clin Pharmacol Toxicol. 2011; 109(5):365-71. DOI: 10.1111/j.1742-7843.2011.00736.x. View

20.

Baumeister H, Hutter N, Bengel J . Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev. 2011; (9):CD008012. PMC: 7389312. DOI: 10.1002/14651858.CD008012.pub3. View